Weight-Loss Pills Replace Injections
The weight-loss industry is experiencing rapid change as big pharma shifts from injectable drugs to pills. The recent launch of the Wegovy pill is regarded as the fastest drug launch ever, with analysts predicting this move will expand access to weight-loss medication.
- The active ingredient in both the Wegovy pill and injection is semaglutide, which mimics a gut hormone called GLP-1 to target areas of the brain that regulate appetite and food intake. - The Wegovy pill, taken once daily, demonstrated significant weight loss in clinical trials, with participants losing an average of 14% to 16.6% of their body weight over about a year, results comparable to the weekly injection. - The manufacturer, Novo Nordisk, has priced the pill similarly to the injection at a list price of roughly $1,350 for a month's supply. However, with insurance and savings programs, the cost can be as low as $25 per month, while self-pay options can range from $149 to $299 depending on the dosage. - Common side effects for the oral version are similar to the injection and primarily gastrointestinal, including nausea, diarrhea, vomiting, and constipation. - The global market for obesity treatments is projected to expand dramatically, with some analysts predicting it could reach $60.53 billion by 2030 and others forecasting a peak of $150 billion by 2035. - Competitors are actively developing their own oral weight-loss medications, including Eli Lilly's orforglipron, which is expected to be approved in 2026. - Novo Nordisk is also developing a next-generation oral medication called amycretin, which targets both GLP-1 and amylin receptors and showed more weight loss at a faster rate than Wegovy in early trials. - Amgen's injectable drug, MariTide, which may only require monthly dosing, showed up to 20% weight loss in a Phase 2 trial, and the company is also in early development of an oral option.
